REN, ENZ, NLY, PWRM, DEI - Market Highlightt From DrStockPick.com!

Jan. 13, 2011 - PRLog -- Enzo Biochem, Inc.  is a leading life sciences and biotechnology company focused on harnessing genetic processes to develop research tools, diagnostics and therapeutics and provides reference laboratory services to the medical community.

Enzo Biochem, Inc. reported improved sequential results for the first fiscal quarter ended October 31, 2010, the result of recent programs to reduce expenses, consolidate activities and expand operations.

The Company's financial condition remained strong, with working capital of $42.1 million. As of October 31, 2010, cash and cash equivalents, plus short term investments in US Treasury Bills, totaled $31.6 million. At November 30, 2010 Enzo’s cash, and cash equivalents and short-term investments were $33.9 million, which exceeded the July 31, 2010 balance by $0.3 million. Cash utilization in operations declined year over year by approximately $1 million to $1.8 million principally due to the reduced loss in the 2011 period. Management’s plan is to move towards being cash flow positive from operations in calendar 2011. There was no debt.

Among the quarter’s highlights (all references are to sequential quarter over quarter results, normalized for an inventory charge and severance of $1.8 million where applicable):

* Enzo Life Sciences, benefiting from increased emphasis on higher margin products, realized a greater than 100% gain in operating income.
* Enzo Clinical Labs increased revenues 6%, while reducing the operating loss 62%.
* Company-wide, gross margin increased $2.0 million or 17%.
* Operating expenses decreased 7%, or to 57% of revenues, from 63%.
* EBITDA, a non-GAAP measure, was $23,000, an improvement of $2.9 million from the prior quarter.
* Net loss for the quarter was reduced 70%.

**********************************************



Power3 Medical Products, Inc. (OTC.BB:PWRM) is a breakthrough proteomics company specializing in the identification of disease footprints in the areas of chemotherapeutic drug resistance and the early detection of breast cancer and neurological diseases. The research platform is centered on the study of proteomics, the science of protein interactions within living cells. With a combined 50+ years of proteomic experience, the Company has identified 334 protein biomarkers with the following potential medical applications:


Breast Cancer   Chemotherapeutic Drug Resistance
Alzheimer's Disease   Leukemia
ALS (Lou Gehrig's Disease)   Gastrointestinal Disease
Parkinson's Disease   Metabolic Syndrome

These discovered and patent-pending biomarkers solve critical challenges facing pharmaceutical and diagnostic companies and are currently being used to design tests to diagnose diseases and discover targets for new drugs to treat the diseases.

Power3 leverages its knowledge of proteomics to detect diseases earlier than currently thought possible. The focus of Power3's efforts is on developing very sensitive patient tests that will enable doctors to diagnose and treat a disease before it becomes life-threatening or debilitating.

BC-SeraPro™ is a blood serum test designed to diagnose breast cancer in individuals. The test is based on proteomic technology in which a blood serum sample drawn from a patient will monitor the concentration of each protein biomarker residing in a panel of blood serum protein biomarkers to determine if a patient has breast cancer. The biomarkers in the panel have been selected for their ability to discriminate breast cancer patients from non-cancerous patients. Power3’s statistical model evaluates the quantitative information of the protein biomarkers and automatically assigns a probability score. The probability score indicates to the physician that the patient “has cancer” or is “cancer-free”.

NuroPro® is a series of three separate and distinct blood serum tests designed to diagnose: Alzheimer’s, Parkinson’s or Lou Gehrig’s disease (ALS) in individuals.

**********************************************

Douglas Emmett Inc  announced that it plans to release its 2010 fourth quarter and full year earnings results after the close of the stock market on Tuesday, February 8, 2011. A live conference call is scheduled for the following day, Wednesday, February 9, 2011 at 11:00 a.m. Pacific Time / 2:00 p.m. Eastern Time. Jordan Kaplan, President and Chief Executive Officer will host the call along with William Kamer, Chief Financial Officer.

Douglas Emmett, Inc., a real estate investment trust, owns and operates office and multifamily properties in California and Hawaii.

**********************************************

Annaly Capital Management, Inc.  released its monthly commentary for January. Through its monthly commentary and blog, Annaly Salvos, Annaly expresses its thoughts and opinions on issues and events in the financial markets. Please visit our website to check out all of the new features and to view the complete commentary with charts and graphs.

Annaly Capital Management, Inc., a real estate investment trust, engages in the ownership, management, and financing of a portfolio of investment securities.

**********************************************

Resolute Energy Corporation  provided an update on its operations in the Bakken Trend. “We continue to be enthusiastic about what we are seeing in the Bakken in terms of production potential and reserve growth,” said Nicholas J. Sutton, Chairman and CEO of Resolute. “Over the course of the last year we successfully entered the Bakken play through our joint venture with GeoResources, our agreement with Marathon Oil as well as through grassroots leasing. Several wells are either completed or waiting on completion, and we have two rigs drilling at this time. We are pleased with this progress and believe that our activities in the Bakken will have a meaningful impact on our reserves and production in 2011.”

Resolute Energy Corporation, an independent oil and gas company, engages in the acquisition, exploration, development, and production of oil, gas, and hydrocarbon liquids.



**********************************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRM.OB).